[Zhenghai Biological (300653) calcium silicate Biological Ceramic Bone repair material Clinical trial Summary meeting successfully heldPokerliveThe curative effect is significantly better than that of imported products]

On April 21, Zhenghai Bio announced that the national multicenter clinical trial summary meeting of calcium silicate bio-ceramic bone repair materials was successfully held in the company. At this conference, the national multicenter randomized controlled clinical trialPokerliveThe key data results were publicly disclosed. The results show that the curative effect of this bone repair material is significantly better than that of imported control products when it is used to fill and repair dental and jaw defects (or insufficient bone mass).

In terms of safety, the performance of the test products is similar to that of the imported control products, and both show good safety.

Hexun self-selected Stock Writer risk Tip: the above content is only the views of the author or guest, does not represent any position of Hexun, and does not constitute any investment advice related to Hexun. Before making any investment decision, investors should consider the risk factors related to investment products according to their own circumstances and consult professional investment advisers if necessary. Hexun tries its best but cannot confirm the authenticity, accuracy and originality of the above content, and Hexun does not make any guarantee or commitment.